About
Aldatu Biosciences develops molecular diagnostic assays based on its proprietary PANDAA adaptive PCR platform to detect and genotype highly variable infectious disease pathogens, including SARS-CoV-2, Lassa virus, Ebola, and HIV drug resistance.
Explore Aldatu Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.